Shots:
- Marea Therapeutics has dosed its first patient with MAR001 in P-IIb (TYDAL-TIMI 78) trial for adults at increased risk of atherosclerotic cardiovascular disease (ASCVD)
- Trial will evaluate MAR001 (300, 450, 900mg; Q4W) vs PBO in ~216 adults with elevated triglycerides & remnant cholesterol at high ASCVD risk, with the 1EP assessing % change from baseline in fasting TG & RC at Wk. 12, & 2EPs incl. changes in fasting VLDL-C & non-HDL-C
- MAR001 is a monoclonal antibody that targets the N-terminal coiled-coil domain of ANGPTL4, which leads to triglyceride-rich lipoprotein hydrolysis & storage in adipose tissue
Ref: Businesswire | Image: Ethris | Press Release
Related News:- Anbogen Therapeutics Reports the US FDA’s IND Clearance of ABT-301 for Metastatic Colorectal Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
